The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder

被引：8
|
作者：
Florea, I. [1 ]
Dragheim, M. [1 ]
Loft, H. [2 ]
机构：
[1] H Lundbeck & Co AS, Mood & Anxiety Disorders, Copenhagen, Denmark
[2] H Lundbeck & Co AS, Biometr, Copenhagen, Denmark
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2012年 / 22卷
关键词：
D O I：
10.1016/S0924-977X(12)70383-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S255 / S256
页数：2
相关论文
共 50 条
  • [1] Long-term safety and tolerability of the multimodal antidepressant Lu AA21004 in subjects with major depressive disorder
    Alam, M.
    Jacobsen, P. L.
    Chen, Y.
    Serenko, M.
    Mahableshwarkar, A. R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S263 - S264
  • [2] Lu AA21004, a multimodal psychotropic agent, in the open-label, long-term treatment of major depressive disorder
    Baldwin, D. S.
    Hansen, T.
    Florea, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S227 - S228
  • [3] Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
    Baldwin, David S.
    Hansen, Thomas
    Florea, Ioana
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1717 - 1724
  • [4] Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder
    Filippov, G.
    Christens, P. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S325 - S325
  • [5] Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Alam, Mohammed Y.
    Jacobsen, Paula L.
    Chen, Yinzhong
    Serenko, Michael
    Mahableshwarkar, Atul R.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (01) : 36 - 44
  • [6] Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
    Berman, Robert M.
    Thase, Michael E.
    Trivedi, Madhukar H.
    Hazel, James A.
    Marler, Sabrina Vogel
    McQuade, Robert D.
    Carson, William
    Baker, Ross A.
    Marcus, Ronald N.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 303 - 312
  • [7] The safety and tolerability of vortioxetine (Lu AA21004) in the treatment of adults with major depressive disorder (MDD): A pooled analysis
    Baldwin, David S.
    Serenko, Michael
    Palo, William
    Lophaven, Soren
    Matz, Jorgen
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2013, 17 : 16 - 17
  • [8] Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
    Mork, A.
    Pehrson, A.
    Brennum, L. T.
    Nielsen, S. Moller
    Zhong, H.
    Lassen, A. B.
    Miller, S.
    Westrich, L.
    Boyle, N. J.
    Sanchez, C.
    Fischer, C. W.
    Liebenberg, N.
    Wegener, G.
    Bundgaard, C.
    Hogg, S.
    Bang-Andersen, B.
    Stensbol, T. Bryan
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 340 (03): : 666 - 675
  • [9] Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study
    Lepola, Ulla
    Hefting, Nanco
    Zhang, Doris
    Hobart, Mary
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (10) : 1403 - 1410
  • [10] A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
    Boulenger, Jean-Philippe
    Loft, Henrik
    Florea, Ioana
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (11) : 1408 - 1416
12345